In a strategic move to deepen its presence in the domestic pharmaceutical market, Emcure Pharmaceuticals has announced the acquisition of the remaining 20.42% stake in Zuventus Healthcare Ltd for a total consideration of ₹724.9 crore. The acquisition, approved by Emcure’s board, will be executed in one or more tranches and paid fully in cash based on a mutually agreed valuation.
Following the completion of this transaction, Zuventus will become a wholly owned subsidiary of Emcure. The deal is expected to close in the September quarter of FY26, enabling Emcure to fully consolidate Zuventus’ financials and align its operations more strategically within the group.
Emcure currently holds a 79.58% stake in Zuventus, a company known for its strong presence in branded generics and specialty pharmaceuticals. The acquisition will allow Emcure to unlock operational synergies, enhance strategic flexibility, and accelerate growth across key therapeutic areas in the Indian market.
The move also reinforces Emcure’s commitment to expanding its domestic healthcare footprint, streamlining decision-making, and delivering greater value to stakeholders. With complete control over Zuventus, Emcure is well-positioned to further strengthen its leadership in India’s evolving pharmaceutical landscape.